Zacks Research Downgrades AngioDynamics (NASDAQ:ANGO) to Strong Sell

AngioDynamics (NASDAQ:ANGO) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday,Zacks.com reports.

ANGO has been the topic of several other reports. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, HC Wainwright increased their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Trading Down 4.5%

NASDAQ:ANGO opened at $13.51 on Thursday. The firm has a fifty day simple moving average of $12.24 and a 200-day simple moving average of $11.35. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $15.19. The company has a market capitalization of $558.37 million, a P/E ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts forecast that AngioDynamics will post -0.27 EPS for the current year.

Institutional Trading of AngioDynamics

Several large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics during the 4th quarter valued at about $27,000. State of Wyoming purchased a new stake in shares of AngioDynamics in the second quarter valued at about $31,000. Russell Investments Group Ltd. grew its holdings in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.